Thus, a potential contribution of elevated 3-MT levels to at least some specific manifestations of L-DOPA-induced dyskinesias and the role of TAAR1 in these processes deserve further detailed investigation. This evidence concerns the gene TAAR1 and drug-induced dyskinesia.